AMENDMENT TO SERVICES AGREEMENT OF FEBRUARY 27TH, 2018

Exhibit 10.21

AMENDMENT TO SERVICES AGREEMENT OF FEBRUARY 27^TH, 2018

THIS AMENDMENT TO THE SERVICES AGREEMENT is made and entered into as of April_, 2022 (“Effective Date”), by and between:

1. Xxxxxx Healthcare Corporation, a company duly organized under the laws of Delaware, having a place of business at Xxx Xxxxxx Xxxxxxx, Xxxxxxxxx, XX 00000 (“Baxter”); and

2. Xxxxxx Healthcare Distribution Ltd a company duly organized under the laws of Israel with its principal place of business at 00 Xxxxxxxxx Xx Xx’xxxxx Xxxxxx (Xxxxxx Xxxxxx)

3. Regentis Biomaterials Ltd., a company duly organized under the laws of Israel with its principal place of business at 00 Xx’xxxx, Xxxxxxxx Xxxxxxxxxx Xxxx, X.X.Xxx 260, Or-Akiva, 3060000, Israel (“Regentis”).

Each of Baxter and Regentis shall sometimes be referred to as a “Party” and collectively, as the “Parties”.

WHEREAS, Xxxxxx Healthcare Corporation (“Baxter”) and Regentis Biomaterials (“Regentis”) did sign a Services Agreement on February 28^th, 2018 (the “Services Agreement”) which envisaged that Regentis would purchase from Teva Medical (Marketing) Ltd (“Teva”) Tisseel for manufacture of Regentis’s product for commercial promotion and sale; and

WHEREAS, Xxxxxx Xxxxxx is an authorized in Israel for distribution of certain products, including Xxxxxx’x Tisseel products; and

NOW, THEREFORE, the Parties wish to amend the Services Agreement such that Regentis shall purchase Tisseel from Xxxxxx Xxxxxx, as Teva Medical (Marketing)Ltd no longer distributes Tisseel in the territory of Israel.

IN WITNESS WHEREOF, the Parties have signed this Agreement as of the Effective Date.

Regentis Biomaterials Ltd.			Xxxxxx Healthcare Corporation
By:	/s/ Xxxx Xxxxxx		By:	/s/ Dror Xxxxxxxxx

Name:	Xx. Xxxx Xxxxxx		Name:	Dror Xxxxxxxxx
Title:	Exec Chairman		Title:	GM
Date:			Date:	March 29, 2022

Xxxxxx Healthcare Distribution Ltd

By: [Signature illegible]